Publicaciones en colaboración con investigadores/as de University of Basel (91)

2024

  1. Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients

    The Lancet Infectious Diseases, Vol. 24, Núm. 1, pp. e59-e68

2023

  1. Adeno-associated virus 2 infection in children with non-A–E hepatitis

    Nature, Vol. 617, Núm. 7961, pp. 555-563

  2. Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 7, pp. 1376-1382

  3. Automatic Discrimination of Species within the Enterobacter cloacae Complex Using Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry and Supervised Algorithms

    Journal of clinical microbiology, Vol. 61, Núm. 4, pp. e0104922

  4. Genomic investigations of unexplained acute hepatitis in children

    Nature, Vol. 617, Núm. 7961, pp. 564-573

  5. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

    Brain : a journal of neurology, Vol. 146, Núm. 11, pp. 4633-4644

  6. Validation of the Collaborative Outcomes study on Health and Functioning during Infection Times (COH-FIT) questionnaire for adults

    Journal of Affective Disorders, Vol. 326, pp. 249-261

2022

  1. Association between use of enhanced recovery after surgery protocols and postoperative complications in colorectal surgery in Europe: The EuroPOWER international observational study

    Journal of Clinical Anesthesia, Vol. 80

  2. Clinical decision-making style preferences of European psychiatrists: Results from the Ambassadors survey in 38 countries

    European Psychiatry, Vol. 65, Núm. 1

  3. Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial

    Frontiers in Oncology, Vol. 12

  4. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up

    European Heart Journal, Vol. 43, Núm. 11, pp. 1059-1103

  5. Effects of copy number variations on brain structure and risk for psychiatric illness: Large-scale studies from the ENIGMA working groups on CNVs

    Human Brain Mapping, Vol. 43, Núm. 1, pp. 300-328

  6. Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial

    European Journal of Neurology, Vol. 29, Núm. 3, pp. 790-801

  7. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

    Cardiovascular research, Vol. 118, Núm. 6, pp. 1385-1412

  8. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

    European Heart Journal, Vol. 43, Núm. 11, pp. 1033-1058

  9. Genetic variants associated with longitudinal changes in brain structure across the lifespan

    Nature neuroscience, Vol. 25, Núm. 4, pp. 421-432

  10. Identification of COVID-19 patients at risk of hospital admission and mortality: a European multicentre retrospective analysis of mid-regional pro-adrenomedullin

    Respiratory Research, Vol. 23, Núm. 1

  11. Mapping genomic loci implicates genes and synaptic biology in schizophrenia

    Nature, Vol. 604, Núm. 7906, pp. 502-508

  12. Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A)

    Journal of Affective Disorders, Vol. 299, pp. 367-376

  13. Procalcitonina es superior a recuento linfocitario, índice neutrófilo/linfocito y proteína C reactiva para la predicción de mortalidad a 30 días de pacientes con COVID-19 en el servicio de urgencias

    Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias, Vol. 34, Núm. 2, pp. 119-127